In vitro Cytotoxic effect of 2-(morpholin-4-yl)-4,5-bis(2”,2”,2”-trinitroethoxy)-1,3,5-Triazine on Human Fibroblasts, Pzeripheral Blood Mononuclear Cells and Breast Cancer Cells

2-(Morpholin-4-yl)-4,5-bis(2”,2”,2”-trinitroethoxy)-1,3,5-triazine having QSAR-predicted anti-tumour activity was tested for the cytotoxicity using MTT and LDH cell viability tests. The work was primarily aimed to study an in vitro cytotoxic effect of the test compound on human fibroblasts, peripheral blood mononuclear cells and breast tumour cell cultures. The experiments were conducted using human fibroblasts, peripheral blood mononuclear cells and BT474 breast cancer cells and allowed to identify effective cytotoxic concentration ant therapeutic range of this compound. It was shown that 2-(morpholin-4-yl)-4,5-bis(2”,2”,2”-trinitroethoxy)-1,3,5-triazine possesses a cytotoxic activity for breast cancer cells with a smaller effect on fibroblasts and blood mononuclear cells. A provisional therapeutic range of this compound is 0.6 - 2.0 μM, two order higher vs. doxorubicin which was used as a reference cytotoxic agent in these experiments. The data obtained suggest that 2-(morpholin-4-yl)-4,5-bis(2”,2”,2”-trinitroethoxy)-1,3,5-triazine is a potential anti-cancer agent and a promising candidate for further anti-tumour efficacy studies.